Ori Elkayam

Ori Elkayam

Auto-generated profile, based on publicly available information

Ori Elkayam

Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
VFVictoria Furer
Victoria Furer
CRChristien Rondaan
Christien Rondaan
MHMarloes W Heijstek
Marloes W Heijstek
Nancy Agmon LevinNancy Agmon Levin
Nancy Agmon Levin
SASander van Assen
Sander van Assen
OEOri Elkayam
Ori Elkayam

1 February 2006 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
IFI Fomin
I Fomin
DCD Caspi
D Caspi
VLV Levy
V Levy
NVN Varsano
N Varsano
YSY Shalev
Y Shalev
OEO Elkayam
O Elkayam
Objective: To assess the efficacy and safety of vaccination against influenza virus in patients with rheumatoid arthritis, with special emphasis on the effect of disease modifying antirheumatic drugs (DMARDs), including tumour necrosis factor α (TNFα) blockers. Methods: 82 rheumatoid patients and 30 healthy controls were vaccinated with a split-virion inactivated vaccine containing 15 μg haemagglutinin (HA) per dose of each of B/Hong Kong/330/2001 (HK), A/Panama/2007/99 (PAN), and A/New Caledonian/20/99 (NC). Disease activity was assessed by tender and swollen joint count, morning stiffness, evaluation of pain, Health Assessment Questionnaire, ESR, and C reactive protein on the day of vaccination and six weeks later. Haemagglutination inhibiting (HI) antibodies were tested by a standard WHO procedure. Response was defined as a fourfold or more rise in HI antibodies six weeks after vaccination, or seroconversion in patients with a non-protective baseline level of antibodies (<1/40). Geometric mean titres (GMT) were calculated to assess the immunity of the whole group. Results: Six weeks after vaccination, a significant increase in GMT for each antigen was observed in both groups, this being higher in the healthy group for HK (p = 0.004). The percentage of responders was lower in rheumatoid patients than healthy controls (significant for HK). The percentage of responders was not affected by prednisone or any DMARD, including methotrexate, infliximab, and etanercept. Indices of disease activity remained unchanged. Conclusions: Influenza virus vaccine generated a good humoral response in rheumatoid patients, although lower than in healthy controls. The response was not affected by the use of prednisone or DMARDs.

19 September 2019 in RMD Open
Verified
Journal Article
Open access
PDF file
VFVictoria Furer
Victoria Furer
CRChristien Rondaan
Christien Rondaan
MHMarloes Heijstek
Marloes Heijstek
SASander van Assen
Sander van Assen
MBMarc Bijl
Marc Bijl
OEOri Elkayam
Ori Elkayam
Objectives The aims of this study were to update the evidence on the incidence and prevalence rates of vaccine preventable infections (VPI) in patients with autoimmune inflammatory rheumatic diseases (AIIRD) and compare the data to the general population when available. Methods A literature search was performed using Medline, Embase and Cochrane library (October 2009 to August 2018). The primary outcome was the incidence or prevalence of VPI in the adult AIIRD population. Meta-analysis was performed when appropriate. Results Sixty-three publications out of 3876 identified records met the inclusion criteria: influenza (n=4), pneumococcal disease (n=7), hepatitis B (n=10), herpes zoster (HZ) (n=29), human papillomavirus (HPV) infection (n=13). An increased incidence of influenza and pneumococcal disease was reported in patients with AIIRD. HZ infection-pooled incidence rate ratio (IRR) was 2.9 (95% CI 2.4 to 3.3) in patients with AIIRD versus general population. Among AIIRD, inflammatory myositis conferred the highest incidence rate (IR) of HZ (pooled IRR 5.1, 95% CI 4.3 to 5.9), followed by systemic lupus erythematosus (SLE) (pooled IRR 4.0, 95% CI 2.3 to 5.7) and rheumatoid arthritis (pooled IRR 2.3, 95% CI 2.1 to 2.6). HPV infection-pooled prevalence ratio was 1.6, 95% CI 0.7 to 3.4 versus general population, based on studies mainly conducted in the SLE population in Latin America and Asia. Pooled prevalence of hepatitis B surface antigen and hepatitis B core antibody in patients with AIIRD was similar to the general population, 3%, 95% CI 1% to 5% and 15%, 95% CI 7% to 26%, respectively. Conclusion Current evidence shows an increased risk of VPI in patients with AIIRD, emphasising that prevention of infections is essential in these patients.

1 February 2004 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
OEOri Elkayam
Ori Elkayam
DCDan Caspi
Dan Caspi
TRTatiana Reitblatt
Tatiana Reitblatt
DCDarlene Charboneau
Darlene Charboneau
JRJeffrey B Rubins
Jeffrey B Rubins

1 June 2010 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
OEOri Elkayam
Ori Elkayam
ABAmir Bashkin
Amir Bashkin
MMMichal Mandelboim
Michal Mandelboim
ILIrena Litinsky
Irena Litinsky
DCDoron Comaheshter
Doron Comaheshter
DPDaphna Paran
Daphna Paran

1 July 2002 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
OEO Elkayam
O Elkayam
MYM Yaron
M Yaron
DCD Caspi
D Caspi
Background: Hepatitis B infection and vaccination against it have been implicated in the potential triggering or flare of some autoimmune diseases, including rheumatoid arthritis (RA). However, the safety of hepatitis B vaccination in patients with pre-existing RA is not known. Objectives: To assess the safety and antibody response of immunisation with a recombinant DNA hepatitis B vaccine in patients with RA. Patients and methods: The study comprised 44 patients with RA, of whom 22 received three doses (the second and third dose being given after one and six months) of a recombinant DNA hepatitis B vaccine (study group) and 22 did not receive the vaccine (control group). Both groups had comparable proportions of women and similar mean age (51 years). Clinical assessment before and two and seven months after the first immunisation included evaluation of daytime pain with a 10 cm visual analogue scale, duration of morning stiffness, and number of tender and swollen joints. Erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) were measured at each visit. Antibodies to hepatitis B surface antigen (HBsAg) were determined by a commercial enzyme linked immunosorbent assay (ELISA) test kit. Results: Hepatitis B vaccination was not associated with an appreciable deterioration in any clinical or laboratory measure of disease. The measures of disease activity of the patients and controls during the study period did not differ significantly: p=0.76 for daytime pain, p=0.1 for morning stiffness, p=0.24 and p=0.3 for tender and swollen joints respectively, p=0.08 for CRP, and p=0.12 for ESR. Fifteen of the 22 patients responded to vaccination, with an antibody level against HBsAg of 10 IU/l after seven months. Lack of response was associated with older age and higher scores of daytime pain. Conclusions: Hepatitis B vaccination is safe in RA and produces antibodies in 68% of the patients.